Revolution Medicines, Inc. (NASDAQ:RVMD) Position Increased by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 3,501.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,287 shares of the company's stock after acquiring an additional 20,696 shares during the quarter. GAMMA Investing LLC's holdings in Revolution Medicines were worth $753,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $34,000. Sterling Capital Management LLC increased its stake in shares of Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares during the period. Kapitalo Investimentos Ltda acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $104,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $154,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Analyst Ratings Changes

RVMD has been the topic of several analyst reports. Wedbush restated an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, May 8th. Oppenheimer raised their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $72.00 price target (down previously from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Guggenheim dropped their price target on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $57.00 price target on shares of Revolution Medicines in a research note on Thursday, May 8th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines has a consensus rating of "Buy" and a consensus price target of $67.08.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded down $0.27 on Friday, hitting $39.66. The company had a trading volume of 2,506,128 shares, compared to its average volume of 1,541,221. The business has a 50-day simple moving average of $39.40 and a 200-day simple moving average of $40.25. The company has a market cap of $7.39 billion, a PE ratio of -9.92 and a beta of 1.10. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter last year, the company posted ($0.70) EPS. On average, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.